{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T23:18:23Z","timestamp":1784675903766,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T00:00:00Z","timestamp":1701475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T00:00:00Z","timestamp":1701475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Sanofi, S.A. de C.V., Mexico"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s40120-023-00567-5","type":"journal-article","created":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T15:02:21Z","timestamp":1701529341000},"page":"141-152","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Bioequivalence Study of Two Tablet Formulations of Clonazepam 2\u00a0mg: A Randomized, Open-Label, Crossover Study in Healthy Mexican Volunteers Under Fasting Conditions"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9190-4286","authenticated-orcid":false,"given":"Luis","family":"Genis-Najera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8463-462X","authenticated-orcid":false,"given":"Maria Elena","family":"Sa\u00f1udo-Maury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,2]]},"reference":[{"key":"567_CR1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/B978-0-444-52898-8.00006-9","volume":"107","author":"A Neligan","year":"2012","unstructured":"Neligan A, Hauser WA, Sander JW. The epidemiology of the epilepsies. Handb Clin Neurol. 2012;107:113\u201333. https:\/\/doi.org\/10.1016\/B978-0-444-52898-8.00006-9.","journal-title":"Handb Clin Neurol"},{"key":"567_CR2","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.yebeh.2015.03.025","volume":"46","author":"D San-Juan","year":"2015","unstructured":"San-Juan D, Alvarado-Le\u00f3n S, Barraza-D\u00edaz J, Davila-Avila NM, Ru\u00edz AH, Anschel DJ. Prevalence of epilepsy, beliefs and attitudes in a rural community in Mexico: a door-to-door survey. Epilepsy Behav. 2015;46:140\u20133. https:\/\/doi.org\/10.1016\/j.yebeh.2015.03.025.","journal-title":"Epilepsy Behav"},{"key":"567_CR3","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1192\/bjp.bp.106.025841","volume":"190","author":"ME Medina-Mora","year":"2007","unstructured":"Medina-Mora ME, Borges G, Benjet C, Lara C, Berglund P. Psychiatric disorders in Mexico: lifetime prevalence in a nationally representative sample. Br J Psychiatry. 2007;190:521\u20138. https:\/\/doi.org\/10.1192\/bjp.bp.106.025841.","journal-title":"Br J Psychiatry"},{"issue":"1","key":"567_CR4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10578-020-01001-9","volume":"52","author":"E Serv\u00e1n-Mori","year":"2021","unstructured":"Serv\u00e1n-Mori E, Gonzalez-Robledo LM, Nigenda G, Quezada AD, Gonz\u00e1lez-Robledo MC, Rodr\u00edguez-Cuevas FG. Prevalence of depression and generalized anxiety disorder among Mexican indigenous adolescents and young adults: challenges for healthcare. Child Psychiatry Hum Dev. 2021;52(1):179\u201389. https:\/\/doi.org\/10.1007\/s10578-020-01001-9.","journal-title":"Child Psychiatry Hum Dev"},{"key":"567_CR5","unstructured":"Basit H, Kahwaji CI. Clonazepam. Treasure Island, FL: StatPearls. 2022. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK556010\/. Accessed 25 July 2023."},{"issue":"3","key":"567_CR6","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1159\/000069089","volume":"49","author":"C Crevoisier","year":"2003","unstructured":"Crevoisier C, Delisle MC, Joseph I, Foletti G. Comparative single-dose pharmacokinetics of clonazepam following intravenous, intramuscular and oral administration to healthy volunteers. Eur Neurol. 2003;49(3):173\u20137. https:\/\/doi.org\/10.1159\/000069089.","journal-title":"Eur Neurol"},{"issue":"7","key":"567_CR7","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1586\/14737175.2015.1056781","volume":"15","author":"Y Shangguan","year":"2015","unstructured":"Shangguan Y, Liao H, Wang X. Clonazepam in the treatment of status epilepticus. Expert Rev Neurother. 2015;15(7):733\u201340. https:\/\/doi.org\/10.1586\/14737175.2015.1056781.","journal-title":"Expert Rev Neurother"},{"issue":"1","key":"567_CR8","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/JCP.0b013e31823fe4bd","volume":"32","author":"AE Nardi","year":"2012","unstructured":"Nardi AE, Freire RC, Mochcovitch MD, et al. A randomized, naturalistic, parallel-group study for the long-term treatment of panic disorder with clonazepam or paroxetine. J Clin Psychopharmacol. 2012;32(1):120\u20136. https:\/\/doi.org\/10.1097\/JCP.0b013e31823fe4bd.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"567_CR9","first-page":"168","volume":"31","author":"G Chouinard","year":"2006","unstructured":"Chouinard G. The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs. J Psychiatry Neurosci. 2006;31(3):168\u201376.","journal-title":"J Psychiatry Neurosci"},{"issue":"1","key":"567_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40981-021-00477-1","volume":"7","author":"K Akita","year":"2021","unstructured":"Akita K, Kumakura Y, Nakajima E, Ishiguro H, Iijima T. Clonazepam for pain due to muscle spasm in a patient with vertebral compression fractures caused by multiple myeloma: a case report. JA Clin Rep. 2021;7(1):75. https:\/\/doi.org\/10.1186\/s40981-021-00477-1.","journal-title":"JA Clin Rep"},{"issue":"12","key":"567_CR11","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1080\/03639045.2019.1689994","volume":"45","author":"MG Davan\u00e7o","year":"2019","unstructured":"Davan\u00e7o MG, Meulman J, Guzm\u00e1n MRP, et al. A randomized, single-dose, two-sequence, two-period, crossover study to assess the bioequivalence between two formulations of clonazepam tablet in healthy subjects. Drug Dev Ind Pharm. 2019;45(12):1982\u20137. https:\/\/doi.org\/10.1080\/03639045.2019.1689994.","journal-title":"Drug Dev Ind Pharm"},{"issue":"12","key":"567_CR12","doi-asserted-by":"publisher","first-page":"pyw083","DOI":"10.1093\/ijnp\/pyw083","volume":"19","author":"K T\u00f3th","year":"2016","unstructured":"T\u00f3th K, Csukly G, Sirok D, et al. Optimization of clonazepam therapy adjusted to patient\u2019s CYP3A status and NAT2 genotype. Int J Neuropsychopharmacol. 2016;19(12):pyw083. https:\/\/doi.org\/10.1093\/ijnp\/pyw083.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"2","key":"567_CR13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.4196\/kjpp.2011.15.2.67","volume":"15","author":"J Kang","year":"2011","unstructured":"Kang J, Park YS, Kim SH, Kim SH, Jun MY. Modern methods for analysis of antiepileptic drugs in the biological fluids for pharmacokinetics, bioequivalence and therapeutic drug monitoring. Korean J Physiol Pharmacol. 2011;15(2):67\u201381. https:\/\/doi.org\/10.4196\/kjpp.2011.15.2.67.","journal-title":"Korean J Physiol Pharmacol"},{"issue":"1","key":"567_CR14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/jms.1141","volume":"42","author":"LE Cavedal","year":"2007","unstructured":"Cavedal LE, Mendes FD, Domingues CC, et al. Clonazepam quantification in human plasma by high-performance liquid chromatography coupled with electrospray tandem mass spectrometry in a bioequivalence study. J Mass Spectrom. 2007;42(1):81\u20138. https:\/\/doi.org\/10.1002\/jms.1141.","journal-title":"J Mass Spectrom"},{"issue":"10","key":"567_CR15","first-page":"985","volume":"48","author":"BL Chauhan","year":"2000","unstructured":"Chauhan BL, Sane SP, Revankar SN, et al. Comparative bioavailability study of clonazepam after oral administration of two tablet formulations. J Assoc Physicians India. 2000;48(10):985\u20137.","journal-title":"J Assoc Physicians India"},{"issue":"5","key":"567_CR16","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/FTD.0b013e3181b1dd76","volume":"31","author":"FM dos Santos","year":"2009","unstructured":"dos Santos FM, Gon\u00e7alves JC, Caminha R, et al. Pharmacokinetic\/pharmacodynamic modeling of psychomotor impairment induced by oral clonazepam in healthy volunteers. Ther Drug Monit. 2009;31(5):566\u201374. https:\/\/doi.org\/10.1097\/FTD.0b013e3181b1dd76.","journal-title":"Ther Drug Monit"},{"issue":"3","key":"567_CR17","first-page":"268","volume":"20","author":"FC Gonz\u00e1lez","year":"2007","unstructured":"Gonz\u00e1lez FC, Mart\u00ednez GH, Archbold Joseph RR, et al. Estudio de bioequivalencia de clonazepam, tabletas de 2 mg, en voluntarios sanos colombianos. IATREIA. 2007;20(3):268\u201374.","journal-title":"IATREIA"},{"key":"567_CR18","unstructured":"Clonazepam TioFarma. PUBLIC ASSESSMENT REPORT of the Medicines Evaluation Board in the Netherlands. Clonazepam TioFarma 0.5 mg and 2 mg, tablets TioFarma b.v., the Netherlands. 2012. https:\/\/www.geneesmiddeleninformatiebank.nl\/pars\/h106590.pdf. Accessed 25 July 2023."},{"key":"567_CR19","unstructured":"The National Health Service (NHS) in England. How and when to take clonazepam. https:\/\/www.nhs.uk\/medicines\/clonazepam\/how-and-when-to-take-clonazepam\/. Accessed 25 July 2023."},{"issue":"8","key":"567_CR20","first-page":"1890","volume":"4","author":"F Micheal","year":"2012","unstructured":"Micheal F, Saranya S, Aparna N, Sridevi CR, Judith MP. Concepts of bioequivalence and its impact on truncated area under curve (AUC) of drugs with long half life in point estimate and intra-subject variability. J Pharm Sci Res. 2012;4(8):1890\u20136.","journal-title":"J Pharm Sci Res"},{"issue":"11","key":"567_CR21","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1177\/0091270005280861","volume":"45","author":"DJ Greenblatt","year":"2005","unstructured":"Greenblatt DJ, Blaskovich PD, Nuwayser ES, Harmatz JS, Chen G, Zinny MA. Clonazepam pharmacokinetics: comparison of subcutaneous microsphere injection with multiple-dose oral administration. J Clin Pharmacol. 2005;45(11):1288\u201393. https:\/\/doi.org\/10.1177\/0091270005280861.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"567_CR22","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1590\/s0004-282x2000000600008","volume":"58","author":"AM Valen\u00e7a","year":"2000","unstructured":"Valen\u00e7a AM, Nardi AE, Nascimento I, Mezzasalma MA, Lopes FL, Zin W. Double-blind clonazepam vs placebo in panic disorder treatment. Arq Neuropsiquiatr. 2000;58(4):1025\u20139. https:\/\/doi.org\/10.1590\/s0004-282x2000000600008.","journal-title":"Arq Neuropsiquiatr"},{"issue":"1","key":"567_CR23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/ADM.0000000000000350","volume":"12","author":"N Ait-Daoud","year":"2018","unstructured":"Ait-Daoud N, Hamby AS, Sharma S, Blevins D. A review of alprazolam use, misuse, and withdrawal. J Addict Med. 2018;12(1):4\u201310. https:\/\/doi.org\/10.1097\/ADM.0000000000000350.","journal-title":"J Addict Med"},{"key":"567_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2021.102656","volume":"64","author":"S Wada","year":"2021","unstructured":"Wada S, Kagatani S, Nakagami H. Quantitative estimation of intra-subject variability in bioequivalence studies of generic solid oral dosage forms by multiple regression analysis. J Drug Deliv Sci Technol. 2021;64: 102656. https:\/\/doi.org\/10.1016\/j.jddst.2021.102656.","journal-title":"J Drug Deliv Sci Technol"},{"key":"567_CR25","unstructured":"US FDA. US FDA approved labelling. Klonopin tablets (clonazepam). 2013. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/017533s053,020813s009lbl.pdf. Accessed 25 July 2023."}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00567-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-023-00567-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00567-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T14:12:15Z","timestamp":1705155135000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-023-00567-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,2]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["567"],"URL":"https:\/\/doi.org\/10.1007\/s40120-023-00567-5","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,2]]},"assertion":[{"value":"26 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Luis Genis-Najera and Maria Elena Sa\u00f1udo-Maury are employees of Sanofi and may own shares and\/or stocks in the company. The authors declare no other conflicts of interest relevant to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was performed in compliance with the principles of the Declaration of Helsinki, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Good Clinical Practice, the Comisi\u00f3n Federal para la Protecci\u00f3n contra Riesgos Sanitarios (COFEPRIS \u2013 Federal Committee for Protection from Sanitary Risks) regulatory requirements, the Mexican guidance NOM 177-SSA1-2013 that establishes the requirements for bioequivalence studies, and the Mexican Regulation of the General Health Law Regarding Health Research. The study protocol (213301410B0051) was approved by the Research Ethics Committee of DEBBIOM (April 13, 2021). An informed consent form was signed by all volunteers before their participation in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}